Mersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer Treatment
By Chris Wack
Mersana Therapeutics shares were up 8% to $1.20 after the company said the U.S. Food and Drug Administration has lifted the clinical hold on its Phase 1 trial of XMT-2056.
The stock is down 84% in the past 12 months.
XMT-2056 is a systemically administered Immunosynthen antibody-drug conjugate that is designed to target a novel human epidermal growth factor receptor 2 epitope and locally activate signaling in both tumor-resident immune cells and in tumor cells.
The Phase 1 open-label trial is investigating XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2, including breast, gastric, colorectal and non-small-cell lung cancers. The dose escalation and dose expansion portions of the trial will evaluate and characterize the relationship of safety, tolerability and exposure of XMT-2056.
The FDA has granted orphan drug designation to XMT-2056 for the treatment of gastric cancer. In August 2022, Mersana entered into a global collaboration providing GSK with an exclusive option to co-develop and commercialize XMT-2056. GSK has not yet exercised this option.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 31, 2023 12:44 ET (16:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness
-
Apple: We Expect New Models and New Chip to Spur Return to iPad Growth
-
Palantir Earnings: AI Platform Drives Strong Start to 2024
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes